

# Carlo Wilke

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5865546/publications.pdf>

Version: 2024-02-01

53  
papers

1,704  
citations

257450

24  
h-index

315739

38  
g-index

56  
all docs

56  
docs citations

56  
times ranked

2638  
citing authors

#	ARTICLE	IF	CITATIONS
1	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 145-156.	10.2	175
2	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. <i>Lancet Neurology</i> , The, 2019, 18, 1103-1111.	10.2	128
3	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 548-558.	10.2	97
4	Genome-wide analyses as part of the international FTLT-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLT. <i>Acta Neuropathologica</i> , 2019, 137, 879-899.	7.7	90
5	Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. <i>EMBO Molecular Medicine</i> , 2020, 12, e11803.	6.9	73
6	Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1270-1272.	1.9	65
7	The wide genetic landscape of clinical frontotemporal dementia: systematic combined sequencing of 121 consecutive subjects. <i>Genetics in Medicine</i> , 2018, 20, 240-249.	2.4	60
8	Serum neurofilament light is increased in multiple system atrophy of cerebellar type and in repeat-expansion spinocerebellar ataxias: a pilot study. <i>Journal of Neurology</i> , 2018, 265, 1618-1624.	3.6	58
9	Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases. <i>European Journal of Human Genetics</i> , 2021, 29, 1325-1331.	2.8	49
10	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. <i>Neurobiology of Aging</i> , 2019, 77, 169-177.	3.1	47
11	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. <i>JAMA Network Open</i> , 2021, 4, e2030194.	5.9	42
12	Atypical parkinsonism in C9orf72 expansions: a case report and systematic review of 45 cases from the literature. <i>Journal of Neurology</i> , 2016, 263, 558-574.	3.6	40
13	Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants. <i>Neurobiology of Aging</i> , 2016, 37, 208.e11-208.e17.	3.1	38
14	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, 500-514.	0.8	36
15	Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. <i>Neurobiology of Aging</i> , 2015, 36, 1072-1074.	3.1	34
16	Solving patients with rare diseases through programmatic reanalysis of genome-phenome data. <i>European Journal of Human Genetics</i> , 2021, 29, 1337-1347.	2.8	34
17	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. <i>NeuroImage</i> , 2019, 189, 645-654.	4.2	33
18	Correlations between serum and CSF pNfH levels in ALS, FTD and controls: a comparison of three analytical approaches. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1556-1564.	2.3	32

#	ARTICLE	IF	CITATIONS
19	Serum Levels of Progranulin Do Not Reflect Cerebrospinal Fluid Levels in Neurodegenerative Disease. <i>Current Alzheimer Research</i> , 2016, 13, 654-662.	1.4	31
20	Beyond ALS and FTD: the phenotypic spectrum of TBK1 mutations includes PSP-like and cerebellar phenotypes. <i>Neurobiology of Aging</i> , 2018, 62, 244.e9-244.e13.	3.1	30
21	Differential early subcortical involvement in genetic FTD within the GENFI cohort. <i>NeuroImage: Clinical</i> , 2021, 30, 102646.	2.7	28
22	Sensorimotor Recalibration Depends on Attribution of Sensory Prediction Errors to Internal Causes. <i>PLoS ONE</i> , 2013, 8, e54925.	2.5	28
23	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. <i>NeuroImage: Clinical</i> , 2019, 24, 102077.	2.7	27
24	Modelling the cascade of biomarker changes in <i>GRN</i>-related frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 494-501.	1.9	27
25	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. <i>Brain</i> , 2022, 145, 1805-1817.	7.6	27
26	Serum neurofilament light chain is increased in hereditary spastic paraplegias. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 876-882.	3.7	26
27	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2020, 133, 384-398.	2.4	26
28	The motor band sign in ALS: presentations and frequencies in a consecutive series of ALS patients. <i>Journal of the Neurological Sciences</i> , 2019, 406, 116440.	0.6	25
29	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 1408-1423.	0.8	24
30	Cerebrospinal Fluid Progranulin, but Not Serum Progranulin, Is Reduced in <b><i>GRN</i></b>-Negative Frontotemporal Dementia. <i>Neurodegenerative Diseases</i> , 2017, 17, 83-88.	1.4	23
31	Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1233-1238.	3.9	22
32	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <sc>NfL</sc> and <sc>pNfH</sc>: A Longitudinal Multicentre Study. <i>Annals of Neurology</i> , 2022, 91, 33-47.	5.3	21
33	The valence of action outcomes modulates the perception of one's actions. <i>Consciousness and Cognition</i> , 2012, 21, 18-29.	1.5	20
34	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 997-1004.	1.9	19
35	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. <i>Annals of Neurology</i> , 2020, 88, 113-122.	5.3	19
36	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. <i>Applied Neuropsychology Adult</i> , 2022, 29, 112-119.	1.2	18

#	ARTICLE	IF	CITATIONS
37	NfL and pNfH are increased in Friedreich's ataxia. <i>Journal of Neurology</i> , 2020, 267, 1420-1430.	3.6	17
38	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. <i>Neurobiology of Aging</i> , 2018, 69, 293.e9-293.e11.	3.1	15
39	Levels of Neurofilament Light at the Preataxic and Ataxic Stages of Spinocerebellar Ataxia Type 1. <i>Neurology</i> , 2022, 98, .	1.1	15
40	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 127.	6.2	12
41	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12185.	2.4	11
42	Neurofilament light chain is a cerebrospinal fluid biomarker in hereditary spastic paraplegia. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1122-1131.	3.7	11
43	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. <i>Molecular Neurodegeneration</i> , 2021, 16, 79.	10.8	9
44	Disease-related cortical thinning in presymptomatic granulin mutation carriers. <i>NeuroImage: Clinical</i> , 2021, 29, 102540.	2.7	8
45	Biallelic Parkin (PARK2) mutations can cause a bvFTD phenotype without clinically relevant parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 145-147.	2.2	6
46	Sensory axonal neuropathy in RFC1-disease: tip of the iceberg of broad subclinical multisystemic neurodegeneration. <i>Brain</i> , 2022, 145, e6-e9.	7.6	6
47	Characteristics of serum neurofilament light chain as a biomarker in hereditary spastic paraplegia type 4. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 326-338.	3.7	6
48	Solving unsolved rare neurological diseases—a Solve-RD viewpoint. <i>European Journal of Human Genetics</i> , 2021, 29, 1332-1336.	2.8	4
49	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 10.	6.2	4
50	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. <i>Cortex</i> , 2022, 150, 12-28.	2.4	2
51	Induced pluripotent stem cells (iPSCs) derived from cerebrotendinous xanthomatosis (CTX) patient's fibroblasts carrying a R395S mutation. <i>Stem Cell Research</i> , 2016, 17, 433-436.	0.7	1
52	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2022, , .	3.1	1
53	A data-driven disease progression model of fluid biomarkers in genetic FTD. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0